On October 12, 2026 Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") reported that it was notified by its licensing partner, Changchun GeneScience Pharmaceutical Co., Ltd. ("GenSci"), that China’s National Medical Products Administration (NMPA) has approved the Marketing Authorization Application (MAA) for CAMCEVI 42 mg, a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate, for the treatment of adult patients with advanced prostate cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Ben Chien, Ph.D., Chairman and Chief Executive Officer of Foresee Pharmaceuticals stated: "We are pleased that our partner GenSci will be launching CAMCEVI 42 mg in China. These efforts will significantly contribute to the growth of our global CAMCEVI franchise."

CAMCEVI is exclusively licensed to GenSci for commercialization in China across all current and pipeline indications, including advanced prostate cancer, central precocious puberty (CPP), and premenopausal breast cancer.

In addition to the NMPA’s approval of CAMCEVI 42 mg for advanced prostate cancer described above, GenSci submitted a supplemental New Drug Application (sNDA) in May 2026 for leuprolide mesylate injectable emulsion for the additional indication of premenopausal breast cancer, which has been accepted by the NMPA for substantive review.

About CAMCEVI 42 mg

CAMCEVI 42 mg is a sustained-release, ready-to-use, 6-month subcutaneous formulation of leuprolide mesylate, a gonadotropin-releasing hormone (GnRH) agonist, offering a less-frequent, ready-to-use dosing alternative to existing therapies.

It is approved for the treatment of adult patients with advanced prostate cancer in the United States (since May 2021), the European Union (since May 2022), and other markets, and, as announced today, in China. Product labeling may differ by country; please refer to the locally approved prescribing information.

(Press release, Foresee Pharmaceuticals, OCT 12, 2026, View Source [SID1234673335])